Masimo (NASDAQ:MASI) Receives “Buy” Rating from BTIG Research

BTIG Research restated their buy rating on shares of Masimo (NASDAQ:MASI) in a report published on Monday,Benzinga reports. The brokerage currently has a $198.00 price objective on the medical equipment provider’s stock.

A number of other research firms have also weighed in on MASI. Zacks Research lowered shares of Masimo from a “strong-buy” rating to a “hold” rating in a report on Friday, October 24th. Weiss Ratings reissued a “sell (d)” rating on shares of Masimo in a research note on Wednesday, October 8th. Bank of America assumed coverage on Masimo in a research report on Monday, November 17th. They set a “neutral” rating and a $162.00 target price on the stock. Wall Street Zen raised Masimo from a “hold” rating to a “buy” rating in a research report on Tuesday, October 14th. Finally, Wells Fargo & Company dropped their price objective on Masimo from $190.00 to $187.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 5th. Four investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $188.40.

Masimo Trading Down 2.4%

Shares of Masimo stock opened at $145.62 on Monday. The stock has a market capitalization of $7.82 billion, a PE ratio of -17.09 and a beta of 1.28. Masimo has a 52 week low of $133.70 and a 52 week high of $194.88. The stock has a 50 day moving average price of $145.59 and a two-hundred day moving average price of $152.72. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.61 and a current ratio of 2.14.

Masimo (NASDAQ:MASI) last announced its quarterly earnings results on Thursday, June 20th. The medical equipment provider reported $1.42 EPS for the quarter. Masimo had a negative net margin of 24.85% and a positive return on equity of 26.54%. The business had revenue of $617.00 million during the quarter. As a group, equities analysts anticipate that Masimo will post 4.1 earnings per share for the current fiscal year.

Institutional Trading of Masimo

A number of large investors have recently bought and sold shares of the company. Twin Tree Management LP purchased a new position in shares of Masimo during the 1st quarter valued at $29,000. MAI Capital Management raised its stake in Masimo by 176.7% in the 2nd quarter. MAI Capital Management now owns 202 shares of the medical equipment provider’s stock valued at $34,000 after acquiring an additional 129 shares during the period. Hilltop National Bank bought a new stake in Masimo in the 2nd quarter valued at about $37,000. Smartleaf Asset Management LLC lifted its holdings in Masimo by 80.0% during the third quarter. Smartleaf Asset Management LLC now owns 306 shares of the medical equipment provider’s stock valued at $44,000 after purchasing an additional 136 shares during the last quarter. Finally, Advisory Services Network LLC bought a new position in Masimo during the third quarter worth about $46,000. 85.96% of the stock is owned by hedge funds and other institutional investors.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.